Aclaris Therapeutics, Inc. Amortization of Intangible Assets
Aclaris Therapeutics, Inc. (ACRS) reported Amortization of Intangible Assets of $75.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-02-27
- Aclaris Therapeutics, Inc. amortization of intangible assets for the quarter ending 2023-12-31 was $19.00K, a 0.00% change year-over-year.
- Aclaris Therapeutics, Inc. amortization of intangible assets for the quarter ending 2023-09-30 was $19.00K, a 0.00% change year-over-year.
- Aclaris Therapeutics, Inc. amortization of intangible assets for the quarter ending 2023-06-30 was $19.00K, a 0.00% change year-over-year.
- Aclaris Therapeutics, Inc. amortization of intangible assets for the quarter ending 2023-03-31 was $19.00K, a 0.00% change year-over-year.
- Aclaris Therapeutics, Inc. amortization of intangible assets for fiscal 2023 was $75.00K, a 0.00% change from fiscal 2022.
- Aclaris Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $75.00K, a 0.00% change from fiscal 2021.
- Aclaris Therapeutics, Inc. amortization of intangible assets for fiscal 2021 was $75.00K, a 0.00% change from fiscal 2020.
- Aclaris Therapeutics, Inc. amortization of intangible assets for fiscal 2020 was $75.00K, a 0.00% change from fiscal 2019.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $38.00K derived: sum of 2 quarters · filed 2024-02-27 | $57.00K derived: sum of 3 quarters · filed 2024-02-27 | $75.00K 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $19.00K 10-Q · filed 2023-11-06 | $38.00K derived: sum of 2 quarters · filed 2023-11-06 | $56.00K 10-Q · filed 2023-11-06 | $76.00K derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2023-06-30 | $19.00K 10-Q · filed 2023-08-07 | $38.00K 10-Q · filed 2023-08-07 | $57.00K derived: sum of 3 quarters · filed 2024-02-27 | $76.00K derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2023-03-31 | $19.00K 10-Q · filed 2023-05-08 | $38.00K derived: sum of 2 quarters · filed 2024-02-27 | $57.00K derived: sum of 3 quarters · filed 2024-02-27 | $76.00K derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $38.00K derived: sum of 2 quarters · filed 2024-02-27 | $57.00K derived: sum of 3 quarters · filed 2024-02-27 | $75.00K 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $19.00K 10-Q · filed 2023-11-06 | $38.00K derived: sum of 2 quarters · filed 2023-11-06 | $56.00K 10-Q · filed 2023-11-06 | $56.00M 10-Q · filed 2022-11-08 | -$55.87M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $19.00K 10-Q · filed 2023-08-07 | $38.00K 10-Q · filed 2023-08-07 | $38.00M 10-Q · filed 2022-08-03 | -$55.89M derived: sum of 3 quarters · filed 2024-02-27 | -$55.87M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $19.00K 10-Q · filed 2023-05-08 | -$55.91M derived: sum of 2 quarters · filed 2024-02-27 | -$55.89M derived: sum of 3 quarters · filed 2024-02-27 | -$55.87M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | -$55.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$55.91M derived: sum of 2 quarters · filed 2024-02-27 | -$55.89M derived: sum of 3 quarters · filed 2024-02-27 | $75.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $19.00K 10-Q · filed 2022-11-08 | $38.00K derived: sum of 2 quarters · filed 2022-11-08 | $56.00M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $19.00K 10-Q · filed 2022-08-03 | $38.00M 10-Q · filed 2022-08-03 | |||||
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-10 | ||||||
| 2020-12-31 | $75.00K 10-K · filed 2023-02-23 | ||||||
| 2019-12-31 | $75.00K 10-K · filed 2022-02-24 | ||||||
| 2019-06-30 | $1.66M 10-Q · filed 2019-08-08 | $3.32M 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $1.66M 10-Q · filed 2019-05-08 | ||||||
| 2018-12-31 | $75.00K 10-K · filed 2021-02-25 | $627.00K 10-K · filed 2019-03-18 | |||||
| 2017-12-31 | $31.00K 10-K · filed 2020-02-25 | ||||||
| 2016-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |